Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2022 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Expands Leadership Team

Appoints Douglas Manion, M.D., FRCP (C), as President and COO WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company...
June 27, 2022 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Expands Leadership Team

Appoints Gail Cawkwell, MD, PhD, as Chief Medical Officer WAYNE, Pa., June 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company...
June 01, 2022 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference

WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
May 16, 2022 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
May 10, 2022 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Clinical Sites Activated for Phase 2b Trial of ATI-1777April Capital Raise Extends Cash Runway Through End of 2025 WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:...
May 03, 2022 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium

WAYNE, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
February 24, 2022 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
February 02, 2022 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference

WAYNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
February 01, 2022 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Expands Leadership Team

Appoints James Loerop as Chief Business Officer WAYNE, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on...
January 11, 2022 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Provides R&D Update

WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...